Retrospective Chart Review on Serum Levels of Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Patients Treated with or without Omega-3 Fatty Acid Ethyl Esters

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080224577

Enrollment

1000

Registered

2019-02-28

Start date

2019-02-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia

Interventions

investigational material(s) Generic name etc : Polyunsaturated Fatty Acids INN of investigational material : - Therapeutic category code : 218 Agents for hyperlipidemias Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients with hyperlipidemia diagnosis are prescribed at least one polyunsaturated fatty acid (PUFA) prescription during the study period. - Patients aged 20 years or more - Patients received the serum test of n-3 and n-6 PUFA at least one or more times during the study period.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
other Blood levels of n-3 and n-6 PUFA before and after PUFA the index date.	—

Secondary

Measure	Time frame
other Changes in serum levels of n-3 and n-6 PUFA from the baseline in patients treated with PUFA. other Change in HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, RLP cholesterol, apoprotein B-48, and hs-CRP before and after treatment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026